Arc 22AI, Vessels, and Expansion
Sanqing advanced its artificial blood vessels, launched Xiao Mei’s medical AI, and expanded into diagnostic booths and in vitro diagnostics. Its record revenue and a new university campus in Kun City left the company poised to grow its medical and research programs.
- Sakura Country agreed to shut down the Fukushima Nuclear Power Plant and upgrade its wastewater treatment system, while Wei Kang secured approval for overseas Xifuning trials and began planning an anti-aging study with Pangu Research Institute.
- Xue Shen and Ding Mian began developing an artificial bladder, and Xue Shen’s artificial blood vessel received approval for clinical trials before Sanqing’s grafts were used in major aortic and dialysis-access surgeries.
- Sanqing’s small-bore artificial blood vessels entered Phase III trials, drawing interest from hospitals and putting Terumo and Maquet under pressure as doctors adopted the grafts for dialysis patients.
- Xiang Gaofei presented Sky Eye 1.0, and Wei Kang introduced Xiao Mei, whose public beta gained attention after she demonstrated diagnoses, health checks, and other services.
- When Xiao Mei’s popularity strained Sanqing’s computing capacity, Wei Kang reduced free consultations and directed Lu Tingfeng to develop an All-Purpose Diagnostic Booth combining tests with AI diagnoses and remote consultations.
- Wei Kang agreed to connect Sanqing’s medical AI to national medical data and launch hospital pilot programs, while experts issued an AI Regulatory White Paper.
- Wei Kang announced that Sanqing had earned $100.1 billion in revenue, and reports linked the company’s growth to Kun City’s economic rise as employees discussed pay, career plans, and further education.
- Wei Kang funded a Gusu University branch campus in Kun City, and the new Gusu University Sanqing Campus opened plans for employee graduate programs, prompting Huang Qin to decide to pursue a doctorate.